Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-01T02:30:51.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A site-wide notice announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to transition updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T02:33:45.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-18T02:21:17.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T03:24:02.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error for the study record, replacing the expected study details with the site’s standard error page.
    Difference
    17%
    Check dated 2026-09-20T01:07:59.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The page shows a new revision tag, v3.6.6, replacing the previous v3.6.5, indicating a platform update. This change does not modify the study data or visible details on the page.
    Difference
    0.1%
    Check dated 2026-08-29T19:40:22.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.